ArticleJournal for immunotherapy of cancer2025
Priming the tumor microenvironment with pembrolizumab and radiotherapy for durable cures in high-risk localized undifferentiated pleomorphic sarcoma and pleomorphic/dedifferentiated liposarcoma.
Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tumorigenesis of well-differentiated and dedifferentiated liposarcoma: 12q amplicon architecture, oncogenic cargo, and evolutionary progression.Cancer metastasis reviews · 2026Review
- Advances in Radiotherapy for Soft Tissue Sarcomas in 2025: A Review.Current oncology reports · 2026Review
- A rare incidence of primary pulmonary undifferentiated pleomorphic sarcoma detected as an endobronchial mass and treated by bronchoscopic resection: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
SU2C-SARC032 establishes addition of perioperative pembrolizumab as a new treatment option for high-risk localized extremity soft tissue sarcoma (STS). For patients with stage III undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma, addition of neoadjuvant and adjuvant pembrolizumab to preoperative radiation therapy (RT) and surgery improved 2-year disease-free survival by 15% compared with RT and surgery alone. This commentary highlights key insights from the trial: (1) the cooperative activity between pembrolizumab and RT, (2) the need for biomarker-driven patient selection, and (3) the potential for circulating tumor DNA to guide adjuvant treatment decisions. Recognizing the heterogeneity of STS, we emphasize the importance of future trials incorporating comprehensive correlative analyses to identify predictors of response and to optimize treatment strategies. Furthermore, we highlight the need for equitable access to advanced diagnostics and personalized treatment approaches so that the benefits of SU2C-SARC032 can be realized for patients with STS throughout the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.